Acumen Pharmaceuticals, Inc.

NasdaqGS ABOS

Acumen Pharmaceuticals, Inc. Shareholders' Equity for the quarter ending September 30, 2024: USD 217.20 M

Acumen Pharmaceuticals, Inc. Shareholders' Equity is USD 217.20 M for the quarter ending September 30, 2024. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqGS: ABOS

Acumen Pharmaceuticals, Inc.

CEO	Mr. Daniel J. O'Connell M.B.A.
IPO Date	July 1, 2021
Location	United States
Headquarters	427 Park Street
Employees	51
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

Key trends

Past 5 years